** Shares of drugmaker Eli Lilly rise 10.2% to $810.13 premarket
** Co says its oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial
** U.S.-listed shares of Lilly's obesity rival Novo Nordisk NOVOb.CO down 3.8%
** Up to last close, LLY down 4.8% YTD
(Reporting by Christy Santhosh in Bengaluru)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.